Jardiance vs Metformin: Cost and Access Head-to-Head

Retail Price: What Each Drug Actually Costs

Metformin is one of the cheapest prescription medications in the United States. A 30-day supply of immediate-release metformin 500 mg twice daily typically costs between $4 and $20 at major retail pharmacies, and many chains (Walmart, Costco, certain grocery-store pharmacies) include it on $4 generic lists [1]. Extended-release formulations cost slightly more, generally $10 to $30 per month, though even these remain among the lowest-priced diabetes drugs on the market.

Jardiance occupies a completely different price bracket. Without insurance, a 30-day supply of empagliflozin 10 mg or 25 mg tablets costs approximately $550 to $620 at most U.S. pharmacies, according to GoodRx and CMS pricing data [2]. That places it in the same tier as other branded SGLT2 inhibitors like dapagliflozin (Farxiga) and canagliflozin (Invokana). Boehringer Ingelheim offers a savings card that can reduce the copay to as low as $10 per month for commercially insured patients, but this card does not apply to Medicare Part D, Medicaid, or other federal programs [3].

The price gap between these two medications is not subtle. A patient paying cash would spend roughly $48 to $240 per year on metformin versus $6,600 to $7,440 per year on Jardiance. That 30-to-1 cost ratio is the single largest factor driving prescribing decisions when glycemic control alone is the clinical goal.

Insurance Coverage and Formulary Placement

Most commercial insurance plans and Medicare Part D formularies list metformin on Tier 1 (preferred generic), which means copays range from $0 to $15 per fill. Some Medicare Advantage plans cover it with no copay at all. Metformin has no prior authorization requirements on any major U.S. formulary.

Jardiance sits on Tier 2 or Tier 3 (preferred or non-preferred brand) on most commercial formularies, producing copays of $25 to $75 per month after deductibles are met [4]. On Medicare Part D, the story gets more complex. Many Part D plans do cover empagliflozin, but patients often face 25% to 33% coinsurance in the coverage gap (the "donut hole"), which can push monthly costs above $150 during that phase. The Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) helps limit total yearly exposure for Medicare enrollees, but the per-fill cost remains higher than any generic [5].

Prior authorization requirements for Jardiance vary by plan. Some insurers require documented metformin intolerance or failure, evidence of established atherosclerotic cardiovascular disease (ASCVD), or a diagnosis of heart failure with reduced ejection fraction before approving coverage. The American Diabetes Association (ADA) 2024 Standards of Care note that SGLT2 inhibitors should be considered regardless of HbA1c in patients with ASCVD, heart failure, or chronic kidney disease, which gives prescribers a clinical basis for authorization requests [6].

HbA1c Lowering: Clinical Efficacy Compared

Both drugs lower HbA1c. They do it through entirely different mechanisms. Metformin (a biguanide) reduces hepatic glucose production and improves peripheral insulin sensitivity. Empagliflozin (an SGLT2 inhibitor) blocks glucose reabsorption in the proximal renal tubule, causing the kidneys to excrete excess glucose in urine.

In the landmark UKPDS 34 trial (N=1,704), metformin reduced any diabetes-related endpoint by 32% compared with conventional dietary therapy in overweight patients with newly diagnosed type 2 diabetes over a median follow-up of 10.7 years [1]. Metformin monotherapy typically lowers HbA1c by 1.0% to 1.5% from baseline in treatment-naive patients, a figure that has been replicated across dozens of trials over three decades [7].

Empagliflozin 25 mg reduced HbA1c by approximately 0.7% to 0.8% from baseline in phase III trials [8]. That is a smaller absolute reduction than metformin achieves as monotherapy, and it is one reason empagliflozin is not positioned as a first-line stand-alone agent. The glycemic benefit of SGLT2 inhibitors also diminishes as eGFR declines below 45 mL/min/1.73 m², though cardiorenal benefits persist at lower kidney function levels [9].

Dr. Silvio Inzucchi, professor of medicine at Yale School of Medicine, has stated: "Metformin remains the backbone of type 2 diabetes pharmacotherapy because of its efficacy, safety profile, and negligible cost. SGLT2 inhibitors add value primarily through their cardiovascular and renal protective effects, not through superior glucose lowering."

Cardiovascular Outcomes: Where the Value Equation Shifts

Cost comparisons lose their simplicity when cardiovascular protection enters the picture. The EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin 10 mg or 25 mg reduced cardiovascular death by 38% (HR 0.62 to 95% CI 0.49, 0.77, P<0.001) and hospitalization for heart failure by 35% (HR 0.65 to 95% CI 0.50, 0.85) compared with placebo in patients with type 2 diabetes and established cardiovascular disease over a median of 3.1 years [2]. All-cause mortality dropped by 32%.

Those numbers changed prescribing practice. The ADA now recommends SGLT2 inhibitors as first-line add-on therapy (or even as first-line in place of metformin) for patients with established ASCVD, heart failure, or diabetic kidney disease [6]. The 2023 ADA/EASD consensus report goes further, stating that cardiorenal benefit should drive drug selection independently of glycemic targets.

Metformin's cardiovascular data come from an older era. The UKPDS 34 showed a 36% reduction in all-cause mortality among overweight patients randomized to metformin versus conventional therapy, but the trial design, patient population, and era of care differ substantially from modern cardiovascular outcome trials [1]. No placebo-controlled cardiovascular outcomes trial of the EMPA-REG design has ever been conducted for metformin, and the 2020 ADA consensus acknowledged this gap.

For a patient with established heart disease paying even $75/month out of pocket for Jardiance, the cost per quality-adjusted life-year may be lower than the sticker price suggests. A 2019 cost-effectiveness analysis published in Diabetes Care estimated that empagliflozin was cost-effective at a willingness-to-pay threshold of $100,000 per QALY gained when prescribed to patients with T2D and established CVD [10].

Generic Availability and Patent Status

Metformin has been available as a generic in the United States since its FDA approval in 1995. Multiple manufacturers produce immediate-release and extended-release formulations, which keeps prices low through market competition. There is no patent protection, no exclusivity period, and no supply constraint.

Jardiance's patent situation is more complex. Boehringer Ingelheim and Eli Lilly hold composition-of-matter and method-of-use patents on empagliflozin that are currently facing challenges. The first generic empagliflozin applications are under FDA review, with potential generic entry expected in the 2025 to 2027 timeframe depending on litigation outcomes [11]. When generics do enter the market, empagliflozin prices could drop by 80% to 90% based on historical patterns with other branded diabetes drugs.

This timeline matters for patients making decisions now. A patient who starts Jardiance today may be paying brand-name prices for another one to two years before generic competition arrives. For patients without strong insurance coverage, that translates to $6,000+ in additional out-of-pocket spending compared with metformin.

Who Gets Access Easily and Who Faces Barriers

Metformin has essentially zero access barriers. It requires no prior authorization, no step therapy, and no specialist referral on any major U.S. insurance plan. Any primary care physician, internist, or endocrinologist can prescribe it. Patients without insurance can purchase it out of pocket for less than the cost of a fast-food meal.

Jardiance access depends heavily on insurance status and clinical indication. A commercially insured patient with documented ASCVD will generally get coverage approved quickly, especially with the manufacturer savings card bringing the copay to $10 to $25 per month. A Medicare patient without established cardiovascular disease or heart failure may face step-therapy requirements (try metformin first), prior authorization paperwork, and formulary restrictions.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the ADA, noted in a 2023 Diabetes Care editorial: "We have a paradox where the patients who would benefit most from SGLT2 inhibitors, those with cardiovascular and kidney disease, are sometimes the ones facing the greatest access barriers due to formulary design and prior authorization burden" [12].

Uninsured patients face the starkest divide. Metformin is available at $4 per month. Jardiance at $600 per month is simply not accessible for most uninsured Americans without patient assistance programs. Boehringer Ingelheim does offer the Jardiance Savings Program and a separate patient assistance program for income-eligible uninsured patients, but enrollment requires documentation and annual renewal [3].

Side-Effect Profiles and Cost of Managing Adverse Events

Metformin's most common side effects (GI distress, diarrhea, nausea) affect 20% to 30% of patients but are usually managed by starting at a low dose and titrating slowly or by switching to extended-release formulations [7]. The feared complication of lactic acidosis is rare (estimated at 3 to 10 cases per 100,000 patient-years) and occurs almost exclusively in patients with significant renal impairment or acute illness [13]. Metformin's side effects rarely generate additional healthcare costs.

Empagliflozin carries different risks. Genital mycotic infections (yeast infections) occur in 5% to 10% of patients, particularly women, and require antifungal treatment [8]. Urinary tract infections are modestly increased. Rare but serious risks include diabetic ketoacidosis (DKA), which can occur even at normal blood glucose levels (euglycemic DKA), and Fournier's gangrene, a necrotizing fasciitis of the perineum that prompted an FDA boxed warning update in 2018 [14]. These adverse events, while uncommon, can generate substantial downstream medical costs when they do occur.

Volume depletion and hypotension are also considerations with empagliflozin, especially in elderly patients taking diuretics. The prescribing information recommends assessing volume status before initiation and monitoring during therapy, adding a layer of clinical attention that metformin does not require [8].

When to Choose Jardiance Despite the Higher Cost

The cost premium for Jardiance is clinically justified in specific populations. Patients with established atherosclerotic cardiovascular disease have the strongest evidence base, drawn directly from the EMPA-REG OUTCOME trial's 38% reduction in cardiovascular death [2]. Patients with heart failure (HFrEF or HFpEF) also benefit, based on the EMPEROR-Reduced (N=3,730) and EMPEROR-Preserved (N=5,988) trials, which showed significant reductions in heart failure hospitalization with empagliflozin regardless of diabetes status [15].

Patients with diabetic kidney disease and an eGFR of 20 to 45 mL/min/1.73 m² represent another group where empagliflozin adds value that metformin cannot, because metformin is contraindicated or dose-limited at eGFR below 30 [9]. The EMPA-KIDNEY trial (N=6,609) showed a 28% reduction in kidney disease progression or cardiovascular death with empagliflozin versus placebo [16].

For patients without cardiovascular disease, heart failure, or CKD, the cost-benefit calculation favors metformin as monotherapy. The ADA 2024 guidelines state: "In the absence of cardiorenal indications, metformin remains the preferred initial pharmacologic agent due to its established efficacy, safety, tolerability, and low cost" [6].

How Prescribers Should Frame the Conversation

A practical approach: start every newly diagnosed type 2 diabetes patient on metformin unless contraindicated (eGFR <30, history of lactic acidosis, or documented intolerance). If the patient also has established ASCVD, heart failure, or CKD stage 3, 4, add empagliflozin concurrently and help the patient manage insurance coverage using manufacturer programs and prior authorization support [6].

For patients already on metformin who develop cardiovascular disease or progressive CKD, adding Jardiance to existing metformin therapy is well-supported. The EMPA-REG OUTCOME population included 74% of patients on background metformin, and the cardiovascular mortality benefit was consistent regardless of baseline metformin use [2].

The bottom line in 2026: metformin costs $4 to $20/month, lowers HbA1c by 1.0% to 1.5%, and has no access barriers. Jardiance costs $550+/month at retail (often $10 to $75 with coverage), lowers HbA1c by 0.7% to 0.8%, and provides proven cardiovascular and renal protection that metformin has never been tested to deliver in a modern outcomes trial. For patients with cardiorenal risk, the cost difference buys a 38% reduction in cardiovascular death. For patients without those risk factors, the extra $6,000+ per year buys marginal glycemic benefit with a different side-effect profile. Match the drug to the patient, not the price tag to the formulary.